Drug Candidate Name
Drug Candidate Description

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Company Name
Company Information
GET IN TOUCH

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Drug Candidates
Therapeutic AreaOncology
IndicationBreast cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationGastrointestinal cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationIntestinal cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationColorectal cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationColon cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationCarcinoid tumour
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationMalignant carcinoid syndrome
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationTriple negative breast cancer
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaNutrition and Weight Loss
IndicationNutritional and metabolic diseases
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationDigestive system disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationLiver disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationFatty liver
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationHepatitis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationNon-alcoholic fatty liver disease
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationNon-alcoholic steatohepatitis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationNutrition disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationObesity
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaGastroenterology
IndicationDigestive system disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationGastrointestinal disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationGastroenteritis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationInflammatory bowel diseases
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaPulmonary/Respiratory Diseases
IndicationRespiratory tract disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationAsthma
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationAllergic asthma
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationLung disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationPulmonary hypertension
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationIdiopathic pulmonary fibrosis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationPulmonary arterial hypertension
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaCardiovascular Diseases
IndicationRespiratory tract disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationLung disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationPulmonary hypertension
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationPulmonary arterial hypertension
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaDiabetis and Endocrinology
IndicationDigestive system disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationLiver disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationFatty liver
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationHepatitis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationNon-alcoholic fatty liver disease
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationNon-alcoholic steatohepatitis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaImmunology
IndicationGastrointestinal disorders
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationGastroenteritis
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationInflammatory bowel diseases
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationAsthma
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationAllergic asthma
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Therapeutic AreaRare Diseases
IndicationPulmonary arterial hypertension
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationCarcinoid tumour
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
IndicationMalignant carcinoid syndrome
Development Phase
Precl
Ph 1
Ph 2
Ph 3
Breakthrough
Orphan Drug
Drug Class
Small molecules
Mechanism of Action
Tryptophan hydroxylase inhibitors
New Molecular Entity
Shelved
Attachments and Links
Non-Confidential Information
Drug candidate and company presentations; links to publications, clinical trials, press releases, videos and medias